EONS has started a new research project, entitled: “Establishing a core set of patient-reported outcomes and measures to enhance supportive care for people treated with targeted therapies for advanced renal cell carcinoma or advanced hepatocellular carcinoma” (abbreviated as PROMs in RCC and HCC).
The aims of the project are:
- To develop a core set of patient-reported outcomes (PROs) and measures (PROMs) that are of relevance to key stakeholders, i.e. people treated with targeted therapies for advanced RCC or advanced HCC, family members, and treating clinicians.
- To explore the level, extent and predictors of impact on core PROs, as measured by core PROMs, in people treated with targeted therapies for advanced RCC or advanced HCC.
This will be a prospective, multinational, mixed-methods study, comprising three consecutive work packages (WP):
WP1: A rapid literature review and multinational online Delphi with strong stakeholder input will be conducted to address the first aim of the project.
WP2: A prospective, multinational, cross-sectional survey will be conducted to address the second aim of the project.
WP3: Dissemination of the project’s findings to relevant audiences and stakeholders.
Project timelines: January 2021 – September 2023
The project is led by Dr Grigorios Kotronoulas (University of Glasgow, UK) together with co-investigators, Professor Daniel Kelly (University of Cardiff, UK), Dr Wendy Oldenmenger (Erasmus MC, University Medical Center Rotterdam, NL), and Dr Amanda Drury (University College Dublin, IRE). Celia Díez de los Ríos de la Serna (EONS Research assistant) will support delivery of the project.
EONS would like to thank Ipsen and Eisai for their support through a restricted educational grant.